Retrospective Study on Ganglionic and Nerve Block Series as Therapeutic Option for Chronic Pain Patients with Refractory Neuropathic Pain
Table 1
Basic characteristics for N = 83 patients included with refractory neuropathic pain syndromes in the head-neck area.
Variable
N = 83 patients
Female gender n (%)
50 (60.2%)
Age in years mean (±SD)
60.4 (±15.7)
Median (25–75 quartile)
57 (51–74)
Duration onset of pain until first infiltration (months) (N = 76), median (quartiles)
19 (4–65)
Medication at the beginning of infiltration series n in %
WHO I: n (%)
20 (24.1%)
WHO II: n (%)
16 (19.3%)
WHO III: n (%)
18 (21.7%)
Coanalgesic drugs:
Antidepressants n (%)
65 (78.3%)
Antiepileptics n (%)
75 (90.4%)
Other
Psychiatric pre‐existing condition n (%)
23 (27.7%)
Depressions n (%)
14 (16.9%)
Infiltration with additional corticosteroid n (%)
69 (83.1%)
Neuropathic pain classified following ICHD 3 [46], given in n (%)
Headache or facial pain attributed to other disorders of cranium, neck, eyes, ears, nose, sinuses, teeth, mouth, or other facial or cervical structure, 11.9
